Aldeyra Therapeutics Inc
ALDX5.145USD
+0.335+6.96%
Trading geöffnet （ET）Kurse um 15 Minuten verzögert
308.93MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Aldeyra Therapeutics Inc Unternehmen
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
Unternehmensinformationen
BörsenkürzelALDX
Name des UnternehmensAldeyra Therapeutics Inc
IPO-datumMay 02, 2014
CEODr. Todd C. Brady, M.D., Ph.D.
Anzahl der mitarbeiter9
WertpapierartOrdinary Share
GeschäftsjahresendeMay 02
Addresse131 Hartwell Avenue
StadtLEXINGTON
BörseNASDAQ Capital Market Consolidated
LandUnited States of America
Postleitzahl02421
Telefon17817614904
Websitehttps://www.aldeyra.com/
BörsenkürzelALDX
IPO-datumMay 02, 2014
CEODr. Todd C. Brady, M.D., Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.42M
+23.16%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Independent Director
14.81K
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Independent Director
Independent Director
--
--
Dr. Stephen G. Machatha, Ph.D.
Dr. Stephen G. Machatha, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Dr. Ben R. Bronstein, M.D.
Dr. Ben R. Bronstein, M.D.
Independent Director
Independent Director
--
--
Ms. Nancy B. Miller-Rich
Ms. Nancy B. Miller-Rich
Independent Director
Independent Director
--
--
Mr. William (Chip) Clark
Mr. William (Chip) Clark
Independent Director
Independent Director
--
--
Mr. Michael (Mike) Alfieri
Mr. Michael (Mike) Alfieri
Principal Financial Officer and Principal Accounting Officer
Principal Financial Officer and Principal Accounting Officer
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Todd C. Brady, M.D., Ph.D.
Dr. Todd C. Brady, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.42M
+23.16%
Dr. Richard H. Douglas, Ph.D.
Dr. Richard H. Douglas, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
--
Mr. Martin J. Joyce
Mr. Martin J. Joyce
Independent Director
Independent Director
23.97K
--
Dr. Gary M. Phillips, M.D.
Dr. Gary M. Phillips, M.D.
Independent Director
Independent Director
14.81K
--
Dr. Neal S. Walker
Dr. Neal S. Walker
Independent Director
Independent Director
--
--
Dr. Stephen G. Machatha, Ph.D.
Dr. Stephen G. Machatha, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Umsatzaufteilung
Keine Daten
Keine Daten
Nach Geschäftsbereich
Nach Region
Keine Daten
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Knoll Capital Management, LLC
9.14%
Perceptive Advisors LLC
8.14%
The Vanguard Group, Inc.
6.21%
BlackRock Institutional Trust Company, N.A.
5.70%
Ardsley Advisory Partners LP
2.92%
Other
67.89%
Aktionäre
Aktionäre
Anteil
Knoll Capital Management, LLC
9.14%
Perceptive Advisors LLC
8.14%
The Vanguard Group, Inc.
6.21%
BlackRock Institutional Trust Company, N.A.
5.70%
Ardsley Advisory Partners LP
2.92%
Other
67.89%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
19.59%
Hedge Fund
16.52%
Investment Advisor/Hedge Fund
9.81%
Private Equity
8.14%
Individual Investor
3.13%
Research Firm
2.42%
Pension Fund
0.17%
Bank and Trust
0.10%
Family Office
0.08%
Other
40.04%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
293
35.88M
59.90%
-7.96M
2025Q1
315
40.31M
67.37%
-4.94M
2024Q4
306
39.84M
66.72%
-5.42M
2024Q3
295
38.52M
64.82%
-5.60M
2024Q2
290
37.23M
62.65%
-8.21M
2024Q1
294
37.04M
62.88%
-7.70M
2023Q4
296
36.84M
62.63%
-6.52M
2023Q3
298
39.89M
68.07%
-12.41M
2023Q2
305
41.03M
70.05%
-8.66M
2023Q1
311
38.11M
64.83%
-12.64M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Knoll Capital Management, LLC
5.48M
9.14%
--
--
Mar 31, 2025
Perceptive Advisors LLC
4.88M
8.14%
-4.40M
-47.44%
Apr 03, 2025
The Vanguard Group, Inc.
3.72M
6.21%
-38.77K
-1.03%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
3.41M
5.7%
-50.91K
-1.47%
Mar 31, 2025
Ardsley Advisory Partners LP
1.75M
2.92%
+600.00K
+52.17%
Mar 31, 2025
Brady (Todd C)
1.42M
2.38%
+267.69K
+23.16%
Apr 14, 2025
Kennedy Capital Management LLC
1.23M
2.06%
-235.10K
-16.01%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.14M
1.9%
+18.27K
+1.63%
Mar 31, 2025
State Street Global Advisors (US)
1.02M
1.71%
-11.99K
-1.16%
Mar 31, 2025
Kingdon Capital Management, L.L.C.
779.00K
1.3%
+779.00K
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Invesco NASDAQ Future Gen 200 ETF
0.8%
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.02%
Vanguard US Momentum Factor ETF
0.02%
Global X Russell 2000 ETF
0.01%
Proshares Ultra Russell 2000
0.01%
iShares Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 Growth ETF
0.01%
Mehr Anzeigen
Invesco NASDAQ Future Gen 200 ETF
Anteil0.8%
iShares Micro-Cap ETF
Anteil0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.02%
Vanguard US Momentum Factor ETF
Anteil0.02%
Global X Russell 2000 ETF
Anteil0.01%
Proshares Ultra Russell 2000
Anteil0.01%
iShares Russell 2000 ETF
Anteil0.01%
ProShares Hedge Replication ETF
Anteil0.01%
ProShares UltraPro Russell2000
Anteil0.01%
iShares Russell 2000 Growth ETF
Anteil0.01%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
